CA-BEHAVIOSEC
21.4.2021 09:02:13 CEST | Business Wire | Press release
BehavioSec , the industry pioneer and technology leader for behavioral biometrics and continuous authentication, today announced new findings that organizations and consumers can feel more comfortable with wider use of behavioral biometrics to safeguard their online digital experiences and identities.
Following a year of digital transformation on a societal level, the demand for better online user experience and a stronger level of digital identity protection has become essential. With a year when the world has seen a combination of personal data theft with new rulings and proposed legislation, like the EU Schrems II in July 2020 and the US National Biometrics Information Privacy Act in August [US Senators Merkley, D-OR and Sanders, I-VT], the need for expert guidance has never been higher. BehavioSec shares this research and a company milestone to highlight how behavioral biometrics can be adopted transparently with clear benefits, and in compliant fashion with comprehensive data protection laws. These include measures like the European General Data Protection Regulation (GDPR), the European Commission’s PSD2/SCA and its Open Banking mandate, the US California Consumer Privacy Act (CCPA) and similar, anticipated requirements of regulations proposed in other regions.
To validate the safe use of behavioral biometrics at a time when headlines are full of allegations about technologies like facial recognition and “deep fake” simulations being abused, BehavioSec sponsored the report, “2021 Global Data Privacy Regulation of Physical & Behavioral Biometrics” by respected industry research firm Goode Intelligence . In the report, Chief Analyst Alan Goode dives into the relevance of current and proposed global privacy and data protection legislation on the successful and compliant adoption of biometrics technology for authentication and identity verification, and addresses the key questions organizations and consumers are asking:
- Where do the next wave of behavioral-based technologies fit?
- How do they impact our delicate balance between security, privacy, and regulation?
- Are they covered under existing and proposed regulation?
- Will behavior-based technology make matters worse - or much better?
Leveraging global bank customer input, extensive research, and legal opinion from attorneys at international law firm Osborne Clarke , the paper outlines how enterprises can confidently use behavioral biometrics while complying with some of the strictest privacy and data protection laws in the world, including GDPR, industry payment regulations like PSD2 SCA, and 3D Secure 2.0 technology.
“As we move more of our personal and business tasks online, it is becoming increasingly important to secure digital channels,” says Goode. “Mobile security is more important than ever before and behavioral biometric technology has proven itself as a vital tool in enabling secure access to digital services, preventing fraudsters from gaining access, all while remaining compliant to GDPR, among others.”
A US-based webcast, “Biometrics & Digital Identity Verification – 2021 Data Protection & Privacy Regulation Insights” will be broadcast on May 25, 2021 featuring a presentation by Alan Goode on his report’s findings and offer further insight on data privacy, digital transformation and fighting fraud and cybercrime using biometrics. Viewers can register to watch the webinar hosted by BehavioSec and IDG including a discussion between CSO’s Bob Bragdon, Alan Goode and an expert panel including Dr. Shane Shook, Financial Crimes Investigator and Venture Consultant at ForgePoint Capital, Jordan Blake, BehavioSec Vice President of Products, and Jake Bernstein J.D., attorney at Focal PLLC and former Washington State Assistant Attorney General.
“It is crucial to proactively stir these debates now on how new technologies define identity and authentication, before assumptions and lack of transparency – even if unintended – irrevocably shake public and policymakers’ trust,” added Jake Bernstein, who specialized in prosecuting consumer protection cases during his time in the U.S. Washington State Attorney General’s office. “The boundary between improving digital trust and triggering privacy and identity crises does not have to be a slippery slope where biometric-based systems are concerned. Yet, perceived missteps and alleged abuse of facial-recognition and other innovations to-date show us what stakeholders, including businesses, have to avoid.”
Additionally, on May 26th at 3:00pm BST/4:00pm CEST, Goode will host a second webcast, “2021 Global Regulation of Physical & Behavioral Biometrics for Digital Identity Verification” , to present his research on the impacts of privacy and data protection regulation on the implementation of biometrics by businesses, particularly across the European Union. As the Founder, CEO, and Chief Analyst of Goode Intelligence, Goode is a respected expert in information security and biometrics and will offer insights on how businesses may be able to consider their specific use cases and possible exceptions for explicit consent according to GDPR regulation. Goode will be joined by BehavioSec and international law firm Osborne Clarke, who BehavioSec commissioned to advise on the regulatory impact to customer deployments of the BehavioSec behavioral biometrics platform , specifically within the German banking sector.
“There’s no question that technology vendors need to continue to work collaboratively with government and business to ensure better protection and experience for consumers and employees while staying fully compliant,” said BehavioSec CEO Neil Costigan. “As the pioneer in this space, we’re offering this research to the market to open the dialogue, and we’re also demonstrating and modeling compliance as a company. Beyond our ongoing support of GDPR and security best practices, we are happy to share our recent SOC2 Type1 certification and our active program for Type 2 and ISO 27001.”
To access this research, the public can download Alan Goode’s report and join the public webcasts with CSO [IDG] in the US on May 25th and with Goode Intelligence in Europe on May 26th .
About BehavioSec
BehavioSec is the industry pioneer and technology leader for behavioral biometrics and continuous authentication, safeguarding millions of users and billions of transactions today.
Deployed across Global 2000 companies to dramatically reduce fraud, friction, threat, and theft, BehavioSec verifies and protects human digital identities by understanding how we uniquely type and swipe across our ever-changing devices. Whether used in the Cloud or on-premises, BehavioSec delivers the superior user experience, precision, and scale needed by organizations to keep customers engaged while catching evasive, real-time attacks other solutions miss.
Founded in the Nordics in 2008 out of groundbreaking research, industry-recognized BehavioSec partners with market leaders and organizations like DARPA, and has earned investment from top investment firms like ForgePoint Capital, Cisco, ABN AMRO, Conor Ventures, and Octopus Ventures. Headquartered in San Francisco, CA with offices worldwide, BehavioSec is ready to help you reduce risk, improve compliance, and digitally transform your distributed workforce and customer experience. www.behaviosec.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005101/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom